News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,820 Results
Type
Article (14170)
Company Profile (103)
Press Release (254547)
Multimedia
Podcasts (53)
Webinars (11)
Section
Business (88534)
Career Advice (491)
Deals (15418)
Drug Delivery (67)
Drug Development (36886)
Employer Resources (54)
FDA (6344)
Job Trends (6276)
News (151090)
Policy (14104)
Tag
Academia (446)
Accelerated approval (4)
Adcomms (7)
Allergies (39)
Alliances (23382)
ALS (40)
Alzheimer's disease (410)
Antibody-drug conjugate (ADC) (55)
Approvals (6390)
Artificial intelligence (128)
Autoimmune disease (10)
Automation (5)
Bankruptcy (149)
Best Places to Work (4407)
BIOSECURE Act (10)
Biosimilars (61)
Biotechnology (40)
Bladder cancer (23)
Brain cancer (18)
Breast cancer (104)
Cancer (792)
Cardiovascular disease (82)
Career advice (425)
Career pathing (13)
CAR-T (29)
CDC (3)
Cell therapy (99)
Cervical cancer (4)
Clinical research (31329)
Collaboration (413)
Compensation (182)
Complete response letters (17)
COVID-19 (775)
CRISPR (27)
C-suite (162)
Cystic fibrosis (42)
Data (854)
Denatured (15)
Depression (15)
Diabetes (88)
Diagnostics (1335)
Digital health (1)
Diversity (2)
Diversity, equity & inclusion (16)
Drug discovery (68)
Drug pricing (78)
Drug shortages (12)
Duchenne muscular dystrophy (48)
Earnings (32665)
Editorial (16)
Employer branding (6)
Employer resources (49)
Events (38130)
Executive appointments (453)
FDA (6894)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (258)
Gene editing (46)
Generative AI (9)
Gene therapy (116)
GLP-1 (368)
Government (1332)
Grass and pollen (3)
Guidances (77)
Healthcare (3617)
Huntington's disease (6)
IgA nephropathy (16)
Immunology and inflammation (43)
Immuno-oncology (1)
Indications (18)
Infectious disease (811)
Inflammatory bowel disease (60)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (58)
Interviews (62)
IPO (5930)
IRA (30)
Job creations (2069)
Job search strategy (387)
Kidney cancer (7)
Labor market (20)
Layoffs (198)
Leadership (4)
Legal (3447)
Liver cancer (19)
Lung cancer (107)
Lymphoma (69)
Machine learning (4)
Management (17)
Manufacturing (196)
MASH (39)
Medical device (1284)
Medtech (1286)
Mergers & acquisitions (9730)
Metabolic disorders (291)
Multiple sclerosis (25)
NASH (14)
Neurodegenerative disease (32)
Neuropsychiatric disorders (11)
Neuroscience (634)
NextGen: Class of 2025 (1600)
Non-profit (608)
Now hiring (31)
Obesity (165)
Opinion (129)
Ovarian cancer (25)
Pain (66)
Pancreatic cancer (24)
Parkinson's disease (50)
Partnered (7)
Patents (141)
Patient recruitment (36)
Peanut (11)
People (29282)
Pharmaceutical (65)
Pharmacy benefit managers (13)
Phase I (8175)
Phase II (13249)
Phase III (11900)
Pipeline (629)
Policy (88)
Postmarket research (1404)
Preclinical (3291)
Press Release (25)
Prostate cancer (58)
Psychedelics (8)
Radiopharmaceuticals (125)
Rare diseases (193)
Real estate (2645)
Recruiting (19)
Regulatory (10259)
Reports (14)
Research institute (573)
Resumes & cover letters (60)
Rett syndrome (1)
RNA editing (4)
RSV (8)
Schizophrenia (44)
Series A (47)
Series B (17)
Service/supplier (3)
Sickle cell disease (33)
Special edition (7)
Spinal muscular atrophy (80)
Sponsored (6)
Startups (1638)
State (2)
Stomach cancer (3)
Supply chain (33)
Tariffs (45)
The Weekly (36)
Vaccines (179)
Venture capitalists (17)
Weight loss (101)
Women's health (9)
Worklife (4)
Date
Last 7 days (186)
Last 30 days (879)
Last 365 days (11454)
2025 (5459)
2024 (12657)
2023 (14420)
2022 (19707)
2021 (20224)
2020 (19124)
2019 (14969)
2018 (11766)
2017 (13959)
2016 (13165)
2015 (15529)
2014 (12446)
2013 (10609)
2012 (11440)
2011 (11948)
2010 (10909)
Location
Africa (316)
Alabama (16)
Alaska (1)
Arizona (59)
Arkansas (3)
Asia (20377)
Australia (2631)
California (2089)
Canada (1033)
China (313)
Colorado (81)
Connecticut (85)
Delaware (73)
Europe (39955)
Florida (404)
Georgia (46)
Idaho (9)
Illinois (239)
India (16)
Indiana (153)
Iowa (1)
Japan (127)
Kansas (62)
Kentucky (15)
Louisiana (2)
Maine (2)
Maryland (299)
Massachusetts (1793)
Michigan (34)
Minnesota (108)
Mississippi (1)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (12)
New Hampshire (7)
New Jersey (905)
New Mexico (8)
New York (615)
North Carolina (438)
North Dakota (2)
Northern California (871)
Ohio (55)
Oklahoma (4)
Oregon (16)
Pennsylvania (504)
Puerto Rico (8)
Rhode Island (10)
South America (505)
South Carolina (5)
Southern California (872)
Tennessee (39)
Texas (275)
United States (8568)
Utah (41)
Virginia (95)
Washington D.C. (38)
Washington State (137)
West Virginia (1)
Wisconsin (21)
268,820 Results for "takeda pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Takeda Pledges $30B in U.S., Argues Against Trump’s ‘Most Favored Nation’ Proposal
Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 trillion over the next 10 years.
May 8, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Takeda Pumps $770M Into Another BridGene Pact to Hit ‘Undruggable’ Targets
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket agreements with Keros Therapeutics, AC Immune and Degron Therapeutics in the past nine months.
February 25, 2025
·
2 min read
·
Tristan Manalac
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.
March 3, 2025
·
2 min read
·
Annalee Armstrong
Business
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while responding positively to the announcement that Julie Kim will take the helm of the Japanese giant in 2026.
January 30, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
May 28, 2025
·
8 min read
Press Releases
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
May 5, 2025
·
3 min read
Press Releases
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
April 8, 2025
·
3 min read
Drug Development
Takeda’s Epilepsy Drug Stumbles in Back-to-Back Phase III Rare Disease Failures
Takeda’s soticlestat, licensed from Ovid Therapeutics, did not significantly reduce seizures in patients with Dravet syndrome and Lennox-Gastaut syndrome, respectively, according to two late-stage readouts on Monday.
June 17, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Takeda Awards $13.8 Million to U.S. Nonprofit Partners to Promote Healthy Eating and Expand STEM Education
April 30, 2025
·
1 min read
Press Releases
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
June 2, 2025
·
16 min read
1 of 26,882
Next
